pI: 8.7973 |
Length (AA): 1213 |
MW (Da): 135619 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | metacyclic. | Smircich P |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | epimastigote. | Smircich P |
Smircich P | Ribosome profiling reveals translation control as a key mechanism generating differential gene expression in Trypanosoma cruzi. |
Ortholog group members (OG5_129498)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_40215 | Acyltransferase family protein |
Candida albicans | CaO19.4066 | C terminus is same as nonallelic CaP19.196 |
Candida albicans | CaO19.7826 | end of contig orf same as C terminus of nonallelic CaP19.4066 potential acyltransferase |
Candida albicans | CaO19.11549 | C terminus is same as nonallelic CaP19.196 |
Candida albicans | CaO19.196 | end of contig orf same as C terminus of nonallelic CaP19.4066 potential acyltransferase |
Caenorhabditis elegans | CELE_Y46G5A.21 | Protein ACL-7 |
Drosophila melanogaster | Dmel_CG4625 | Dihydroxyacetone phosphate acyltransferase |
Escherichia coli | b4041 | glycerol-3-phosphate O-acyltransferase |
Homo sapiens | ENSG00000116906 | glyceronephosphate O-acyltransferase |
Leishmania braziliensis | LbrM.20.1120 | dihydroxyacetonephosphate acyltransferase;with=GeneDB:LmjF34.1090 |
Leishmania donovani | LdBPK_341170.1 | dihydroxyacetone phosphate acyltransferase, putative |
Leishmania infantum | LinJ.34.1170 | dihydroxyacetonephosphate acyltransferase;with=GeneDB:LmjF34.1090 |
Leishmania major | LmjF.34.1090 | dihydroxyacetonephosphate acyltransferase |
Leishmania mexicana | LmxM.33.1090 | dihydroxyacetonephosphate acetyltransferase |
Loa Loa (eye worm) | LOAG_00301 | hypothetical protein |
Mycobacterium leprae | ML1246 | PROBABLE GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE PLSB2 (GPAT) |
Mus musculus | ENSMUSG00000031985 | glyceronephosphate O-acyltransferase |
Mycobacterium tuberculosis | Rv2482c | Probable glycerol-3-phosphate acyltransferase PlsB2 (GPAT) |
Mycobacterium tuberculosis | Rv1551 | Possible acyltransferase PlsB1 |
Mycobacterium ulcerans | MUL_1547 | glycerol-3-phosphate acyltransferase |
Schmidtea mediterranea | mk4.000360.09 | Dihydroxyacetone phosphate acyltransferase |
Schmidtea mediterranea | mk4.000360.08 | Dihydroxyacetone phosphate acyltransferase |
Trypanosoma brucei gambiense | Tbg972.4.3170 | dihydroxyacetone phosphate acyltransferase, putative,glycerol-3-phosphate acyltransferase, putative |
Trypanosoma brucei | Tb927.4.3160 | dihydroxyacetone phosphate acyltransferase, putative |
Trypanosoma cruzi | TcCLB.506435.270 | dihydroxyacetone phosphate acyltransferase, putative |
Trypanosoma cruzi | TcCLB.504055.40 | dihydroxyacetone phosphate acyltransferase, putative |
Toxoplasma gondii | TGME49_221518 | hypothetical protein |
Toxoplasma gondii | TGME49_203570 | acyltransferase domain-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.3160 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.3160 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.3160 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.4.3160 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b4041 | Escherichia coli | essential | goodall |
TGME49_221518 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_203570 | Toxoplasma gondii | Probably non-essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.6
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | glyceronephosphate O-acyltransferase | Compounds | References |